Selective defect in the antibody response to type b in children with recurrent infections and normal serum IgG subclass levels

1988 ◽  
Vol 81 (6) ◽  
pp. 1175-1179 ◽  
Author(s):  
D AMBROSINO ◽  
D UMETSU ◽  
G SIBER ◽  
G HOWIE ◽  
T GOULARTE ◽  
...  
Keyword(s):  
Antibody Response ◽  
Normal Serum ◽  
Igg Subclass ◽  
Recurrent Infections ◽  
Type B ◽  
Serum Igg

Letter to the editor: Humoral immunodeficiencies in Down syndrome: Serum IgG subclass and antibody response to hepatitis B vaccine

2005 ◽  
Vol 37 (S7) ◽  
pp. 231-233 ◽  
Author(s):  
Maria A. Avanzini ◽  
Virginia Monafo ◽  
Mara De Amici ◽  
Giuseppe R. Burgio ◽  
Alessandro Plebani ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Hepatitis B ◽  
Antibody Response ◽  
Hepatitis B Vaccine ◽  
Igg Subclass ◽  
Serum Igg ◽  
Letter To The Editor

scholarly journals Evaluation of assays of serum IgG subclasses and IgG antigen-specific antibodies in the investigation of recurrent infection

2000 ◽  
Vol 37 (3) ◽  
pp. 326-329 ◽  
Author(s):  
G F Read ◽  
P E Williams
Keyword(s):  
Clinical Outcome ◽  
Clinical Immunology ◽  
Recurrent Infection ◽  
Igg Subclasses ◽  
Igg Subclass ◽  
Recurrent Infections ◽  
Protein Antigens ◽  
Specific Antibodies ◽  
Serum Igg ◽  
Regional Service

Patients who have recurrent infections require laboratory investigation for possible underlying immunodeficiency. We retrospectively evaluated the usefulness of two relevant assays (serum IgG subclass concentration and levels of IgG antigen-specific antibodies to a panel of relevant carbohydrate and protein antigens) in the management of patients referred to a regional clinical immunology service over a 3-year period. Of 97 patients for whom both assays were performed, five (5·2% ) had a low result for IgG subclasses but this did not influence the management of any patient; 51 patients (53%) had a low result for antigen-specific antibodies and this influenced management in 43 cases. We conclude that knowledge of the serum IgG subclass concentrations is of dubious relevance and this calls into question whether the assay should continue to be offered. This regional service has ceased to perform the assay routinely in such patients. Our findings require confirmation by a larger multicentre study that should assess the clinical outcome of any changes in practice.

Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-α therapy

1997 ◽  
Vol 55 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Lucile Musset ◽  
Pascale Ghillani ◽  
Françoise Lunel ◽  
Patrice Cacoub ◽  
Pascale Cresta ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Interferon Α ◽  
Igg Subclass ◽  
Hepatitis C Virus Infection ◽  
Serum Igg

scholarly journals Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1478
Author(s):  
Davide Firinu ◽  
Andrea Perra ◽  
Marcello Campagna ◽  
Roberto Littera ◽  
Federico Meloni ◽  
...  
Keyword(s):  
Observational Study ◽  
Antibody Response ◽  
Messenger Rna ◽  
Healthy Subjects ◽  
Booster Dose ◽  
Spike Protein ◽  
National Guidelines ◽  
Vector Vaccine ◽  
Boost Vaccination ◽  
Serum Igg

In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19. Methods: healthy subjects naïve for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (TFULL) and 15 (T15W) weeks after booster dose. Results: The median IgG anti-S-RBD levels at TFULL of Chad/BNT group were significantly higher than the BNT/BNT group and ChAd/ChAd. Those of BNT/BNT group were significantly higher than ChAd/ChAd. IgG anti-S-RBD of BNT1dose/CoV2 group were similar to BNT/BNT, ChAd/BNT and ChAd/Chad group. The levels among COVID-19 convalescents were significantly lower than ChAd/BNT, BNT/BNT, ChAd/Chad and BNT1dose/CoV2. The proportion of subjects reaching an anti-S-RBD titer >75 AU/mL, correlated with high neutralizing titer, was 94% in ChAd/BNT and BNT/BNT, 60% in BNT1dose/CoV2, 25% in ChAd/ChAd and 4.2% in convalescents. At T15W the titer of ChAd/BNT was still significantly higher than other vaccine schedules, while the anti-S-RBD decline was reduced for ChAd/ChAd and similar for other combinations. Conclusion: Our data highlight the magnitude of IgG anti-S-RBD response in ChAd/BNT dosing, supporting the current national guidelines for heterologous boosting

Sign in / Sign up

Export Citation Format

Share Document